- Open Access
COVID-19 multidisciplinary high dependency unit: the Milan model
Respiratory Research volume 21, Article number: 260 (2020)
COVID-19 is a complex and heterogeneous disease. The pathogenesis and the complications of the disease are not fully elucidated, and increasing evidence shows that SARS-CoV-2 causes a systemic inflammatory disease rather than a pulmonary disease. The management of hospitalized patients in COVID-19 dedicated units is advisable for segregation purpose as well as for infection control. In this article we present the standard operating procedures of our COVID-19 high dependency unit of the Policlinico Hospital, in Milan. Our high dependency unit is based on a multidisciplinary approach. We think that the multidisciplinary involvement of several figures can better identify treatable traits of COVID-19 disease, early identify patients who can quickly deteriorate, particularly patients with multiple comorbidities, and better manage complications related to off-label treatments. Although no generalizable to other hospitals and different healthcare settings, we think that our experience and our point of view can be helpful for countries and hospitals that are now starting to face the COVID-19 outbreak.
On January 30, 2020, the World Health Organization (WHO) designated an outbreak of a novel coronavirus not seen before in humans to be a “public health emergency of international concern” . On March 11, 2020, WHO declared the coronavirus disease 2019 (COVID-19) outbreak a global pandemic [2, 3]. In March 2020, Italy became the epicenter for COVID-19 in Europe, and the second most affected country after China worldwide . Up to 20% of suspected and confirmed patients with Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infection develop severe hypoxemia and require some forms of ventilatory support, such as high-flow nasal cannula (HFNC), non-invasive (NIV) or invasive mechanical ventilation (IMV). Furthermore, other important challenges have been identified soon after the disease development, including cardiac, renal, neurological and thromboembolic complications [5,6,7,8,9]. A rapid widespread of units dedicated to COVID-19 patients has characterized the public health scenario worldwide, including Italy and its more affected region, Lombardy . The high number of people who got infected by SARS-CoV-2 and who developed acute respiratory failure (ARF) rapidly overcame the number of intensive care unit (ICU) beds in Lombardia, and this led several high dependency units (HDU) to be converted in specific COVID-19 HDU. The process of developing a COVID-19 HDU, along with its standard operating procedures (SOPs), could be useful for those who are preparing themselves for the COVID-19 epidemic or to implement already existing COVID-19 HDU. The aim of this article is to present the organization of the COVID-19 HDU of the Policlinico Hospital in Milan, Italy. Although we are aware that the procedures adopted in our hospital cannot be entirely generalized in other hospitals and healthcare systems, we think that the information of the paper should be shared with the clinical community in order to help colleagues to develop or implement a multidisciplinary COVID-19 HDU.
The multidisciplinary COVID-19 HDU
The Fondazione IRCCS Ca′ Granda Ospedale Maggiore Policlinico is the oldest hospital in Milan, located in the city centre, and organized in different pavilions (Fig. 1, online supplements). The pavilion-based structure has clear advantages for the management of infectious diseases, including COVID-19, since it allows microbiological segregation. During the COVID-19 outbreak in Milan, four different pavilions of the Policlinico Hospital have been entirely allocated for the management of COVID-19 patients, including one emergency room (ER), four ICUs, two HDUs and four low-dependency units. Our respiratory HDU was converted to COVID-19 HDU and the entire pulmonary team (pulmunologists, nurses, respiratory physicians) was involved in the care of COVID-19 patients. The same process of segregation has been adopted by other services (e.g radiology). The number of HDU and ICU COVID-19 beds available in our hospital have been about 3 times the number of HDU and ICU beds available before the start of the pandemic. Eligible COVID-19 patients for the 41-bed COVID-19 HDU have been discussed on a case-by-case basis to identify the best suitable setting, according to the following criteria: 1) the severity of ARF evaluated through the PaO2/FiO2 ratio; 2) The presence of immunosuppression; and 3) the presence of a colonization/infection with a multi-drug resistant (MDR) bacteria. Key information to triage COVID-19 patients who are about to be admitted to the COVID-19 HDU are: 1) The last PaO2/FiO2 ratio and type of respiratory support (e.g. HFNC, helmet Continuous Positive Airway Pressure (CPAP), and NIV); 2) The presence of an infection/colonization with a MDR bacteria; 3) The state of consciousness/anxiety/sedation; 4) The indication concerning the Do Not Resuscitate (DNR)/Do Not Intubate (DNI) status; 5) Patient’s performance status; 6) The presence of signs of sepsis; 7) The severity of involvement of other organs (heart, kidney, liver, central nervous system). The COVID-19 HDU do not only admits patients coming to the ER but also acts as a catchment area for other COVID-19 units (including ICU) of the Policlinico hospital and other hospitals in Lombardy.
We involved other healthcare professionals in our multidisciplinary team. Cardiologists, infectious diseases specialists, rheumatologists, intensivists and respiratory physiotherapists are fundamental components of the COVID-19 HDU, working together in a multidisciplinary team, see Table 1. The multidisciplinary approach to COVID-19 has a crucial role for several reasons. Firstly, the pathogenesis and the complications of the disease are not fully elucidated, and increasing evidence shows that SARS-CoV-2 causes a systemic inflammatory disease rather than a pulmonary disease [5,6,7,8,9, 11, 12]. Secondly, no licensed drugs exist for COVID-19, and the majority of treatments are off-label or within clinical trials [13,14,15,16]. Thirdly, management of complications and adverse events of drugs require a multidisciplinary approach, especially in patients with multiple comorbidities . Finally, a daily clinical discussion with other COVID-19 units is crucial to quickly identify patients who would benefit from invasive support or transfer to a low-dependency unit.
Standard operating procedures of the COVID-19 HDU
Initial assessment of patient
A minimum bundle of tests through a systematic approach is implemented on the COVID-19 HDU. Additional tests should be considered on a case-by-case basis according to clinical condition and specific comorbidities, see Table 2.
COVID-19 is a very heterogeneous disease and the type and severity of ARF depends on the interaction among multiple factors including the time from symptoms onset and admission to HDU, the severity of the infection, the host response, physiological reserve and comorbidities, and the ventilatory responsiveness of the patient to hypoxemia [9, 18, 19]. A systematic review and meta-analysis of 25 randomized control trials (RCTs) showed that a liberal oxygen strategy (SpO2 targets higher of 96%) is associated with increased risk of hospital mortality in acutely ill patients . In the HDU FiO2 is settled with the aim of target SpO2 of 92–96%. Despite international guidelines recommending only cautious trials of NIV in immunocompetent patients with ARF due to community-acquired pneumonia (CAP), RCTs showed that the possible application of Positive End-expiratory Pressure (PEEP) in CAP patients is able to recruit alveoli leading to a rapid improvement in oxygenation [21,22,23]. However, NIV and CPAP should not delay endo-tracheal intubation in patients who could benefit of invasive ventilation . In particular, intubation should be prioritized in patients treated with CPAP or NIV presenting with clinical signs of excessive inspiratory efforts, to avoid excessive intrathoracic negative pressures and self-inflicted lung injury . Levels of PEEP and pressure support during CPAP or NIV should be individualized to obtain the lowest level of support able to oxygenate the patient without increase the risk of both lung and cardiovascular side effects. A particular consideration shall be given to high PEEP pressures considering the increase risk of pneumothorax/pneumomediastinum. Furthermore, high PEEP in a poorly recruitable lung tends to result in severe haemodynamic impairment and fluid retention . This is the rationale for the implementation in the SOPs of the COVID-19 HDU of the “zero end-expiratory pressure (ZEEP)-PEEP test” to tailor PEEP level in each single patient . Patient posture during NIV is crucial to optimize ventilation. In particular, slumped posture should be avoided and early mobilization for all patients is encouraged. Prone positioning or lateral position could be also considered in these patients according to imaging and clinical status [28, 29]. Preliminary evidences show improvements in oxygenation parameters with prone positioning in patients with COVID-19 receiving NIV or HFNC . However, clinicians should be aware that prone positioning can be also harmful . Indeed, prone positioning of patients with relatively high compliance results in a modest benefit at the price of a high demand for stressed human resources . Close blood gas analysis (BGA) and clinical evaluation are performed after position changes to verify the advantages. Finally, all the medical devices for non-invasive respiratory support have a risk of droplet spreading [33, 34]. The risk of infection spread is higher with HFNC (a surgical mask should be put on by the patient) and lower with helmet CPAP . This is one of the reasons why we decided to prefer helmet CPAP in the COVID-19 HDU. CPAP and NIV should be equipped with a double filter (in and out) to minimize the risk of droplet spreading. Heat and moisture exchanger (HME) filters should be positioned before the PEEP resistance and on inspiratory circuit of Helmet. However, the use of out-put filter positioned before the PEEP resistance can increase the pressure of 2.5–5 cmH20 (high variability of data) in the circuit. Aerosol and warm humidifiers are avoided in our HDU to prevent droplet diffusion.
▪ Remdesivir (clinical trial)
Despite several randomized trials being underway to evaluate the safety and efficacy of different antiviral agents, data supporting the use of any anti-viral agents in COVID-19 have been mostly extrapolated from case series or in vitro experiments [14,15,16, 35, 36]. The multidisciplinary team of the COVID-19 HDU discussed the pro and cons and the evidence of introducing an antiviral drug in patients with COVID-19 pneumonia and acute respiratory failure, and initially decided to consider the use of hydroxychloroquine for all patients in absence of contraindications [35,36,37]. In vitro, hydroxychloroquine hampers low pH-dependant steps of viral replication resulting in antiviral activity . Retrospective and open-label non-randomized clinical trial in patients hospitalized with COVID-19 showed that hydroxychloroquine was associated with decreased mortality and viral load reduction [35, 36]. Before starting hydroxychloroquine treatment, an electrocardiogram (EKG) was performed given the risk of QT prolongation and interactions with other drugs was checked . EKG was usually repeated every 48 h to assess the risk of QTc prolongation. Indeed, studies have highlighted the potential for toxicity of hydroxychloroquine, particularly QTc prolongation and risk of arrhythmias [40, 41]. However, accumulating data from trials and observational studies suggested that hydroxychloroquine do not provide a clinical benefit regards of mortality or leght of hospital stay for patients with COVID-19 [40,41,42]. According to this data the multidisciplinary team decided to not routinely use hydroxychloroquine in COVID-19 patients. After multidisciplinary discussion, the COVID-19 team decided again the use of lopinavir/ritonavir according to evidence showing no benefit of this treatment beyond standard of care . Furthermore, lopinavir/ritonavir is associated with gastrointestinal adverse events leading to discontinuation of treatment in 14% of the patients within a clinical trial . Remdesivir, a broad-spectrum antiviral with potent in vitro activity against a range of RNA viruses, has shown in vivo activity against related coronavirus MERS-CoV and SARS-CoV-2 animal models [15, 16]. Furthermore, preliminary data from randomized trials suggest clinical benefit of remdesivir in hospitalized COVID-19 patients [14, 43]. In the COVID-19 HDU, remdesivir is used within a clinical trial programme .
▪ Methylprednisolone alone in patients with all the following criteria: CPAP / NIV support; procalcitonin < 1 μg/L; active inflammation (C-reactive Protein> upper limit of normal and/or fever without alternative origin); no clinical signs of sepsis. Methylprednisolone dosage is 80 mg/die intravenous (consider 120 mg/die in severe cases).
▪ Anakinra (anti IL-1) and methylprednisolone in patients with all the following criteria: CPAP / NIV support; ferritin > 1.000 ng/ml; procalcitonin (PCT) < 1 μg/L; no clinical signs of sepsis; no other biologics. Anakinra dosage is 200 mg subcutaneously every 8 h followed by 100 mg every 6 h according to inflammatory markers and ferritin, associated with methylprednisolone dosage is 80 mg/die intravenous (consider 120 mg/die in severe cases) [5, 44]. The most common Anakinra side effects are wheal at the injection site and neutropenia .
▪ Tocilizumab (anti IL-6) in patients with all the following criteria: IL6 > 5 x ULN; transaminase levels lower than × 5 upper limit of normal; neutrophils > 500 cell/mm3; platelets > 50,000 cell/mm3; no clinical signs of sepsis; no diverticulitis nor bowel perforation; no systemic or cutaneous infection; no other biologics. Tocilizumab dosage is (anti IL-6) 8 mg/kg (weight > 30 kg) or 12 mg/kg (weight < 30 kg). Adverse events are: upper respiratory tract skin and soft tissue infections; headache; transient decreases in neutrophil count; abnormal liver function tests; nasopharyngitis; and diarrhea [46, 47].
Accumulating evidence suggests that a subgroup of patients with severe COVID-19 have laboratory and clinical evidence of an exuberant inflammatory response. This constellation of features is reminiscent of a family of syndromes broadly gathered under the umbrella of cytokine storm syndrome, in which hyperinflammation and multi-organ disease arise through excessive cytokine release from uncontrolled immune activation, with persistent fevers, elevated inflammatory markers, and elevated pro-inflammatory cytokines [11, 12]. These “endotypes” have been associated with critical and fatal illnesses . Therefore, identification of biomarkers such as ferritin or IL-6, and treatment of these biomarkers stimulating hyper-inflammation using approved or under-evaluation therapies is of paramount importance to reduce the rising mortality. Indeed, predictors of mortality from a multicentre retrospective study of confirmed COVID-19 cases in China included elevated ferritin and IL-6, suggesting that mortality might be due to virally driven hyper-inflammation . Therapeutic options to target specific pathways leading to hyper-inflammation include selective cytokine blockade agents such as anakinra or tocilizumab [5, 44, 49]. However, no randomized control trial has been published to support the use of these drugs in COVID-19 disease. The use of these drugs has been extrapolated from case series, observational studies or is based on trials on other diseases that leads to viral-driven hyper-inflammation [12, 44, 49,50,51,52,53]. Finally, the use of steroid therapy to control the hyper-inflammation is largely debated. The WHO, the Centers for Disease Control (CDC) and the Infectious Diseases Society of America (IDSA) does not recommend glucocorticoids in patients with COVID-19 pneumonia because they have been associated with an increased risk for mortality in patients with influenza and delayed viral clearance in patients with Middle East respiratory syndrome coronavirus (MERS-CoV) infection [54,55,56]. However, a recent observational study from China suggested that the use of corticosteroids may reduce mortality in COVID-19 patients with Acute Respiratory Distress Syndrome (ARDS), so systemic corticosteroids could be considered in moderate to severe ARDS in our unit, as suggested by Surviving Sepsis Campaign [5, 57]. During the writing of the present manuscript, dexamethasone has been approved in the United Kingdom for all hospitalized patients with COVID-19 requiring oxygen .
Antibiotic coverage is considered in case at least one of the following criteria is present: 1) WBC < 4.000 o > 10.000 (and neutrophilia); 2) PCT > 1 μg/L (or PCT > 0.5 μg/L on two consecutive determination); 3) Clinical-radiological signs of bacterial infection. Antibiotic selection follows the latest IDSA/ATS CAP Guidelines .
Inappropriate antibiotic use may reduce their availability and broad-spectrum antibiotics in particular may lead to Clostridium difficile infection and antimicrobial resistance [21, 22]. For these reasons, we consider antibiotic therapy only in case of criteria suggesting risk of co-infection or super-imposed infection with bacteria. Broad spectrum antibiotic coverage is based on risk factors for Methicillin-Resistant Staphylococcus aureus (MRSA) or Pseudomonas aeruginosa . Empiric broad spectrum antibiotic coverage is continued while obtaining definitive cultural data . In patients tested positive for Influenza virus A or B, oseltamivir 75 mg 1 tablet every 12 h is initiated with the aim of reducing the risk of death [59, 60]. Finally, in case of treatment with a macrolides or respiratory fluoroquinolones, EKG is performed on daily basis especially if the patient is on hydroxychloroquine or other medications that prolong QT interval [39, 42, 61,62,63,64,65].
In patient with a low-risk of bleeding (normal clotting time with PT < 1.5, platelets > 100,000 mm3, no active bleeding, and no risk of trauma), an individualized prophylaxis with enoxaparin sodium is given subcutaneously (either 4000 IU every 24 h, or 100 IU/kg every 24 h, or 70 IU/kg every 24 h, according to disease severity and inflammatory and coagulative markers). In case of creatinine clearance < 30 ml/min, Heparin calcium at starting dose of 5000 Units/ 0.2 ml solution × 3 daily for subcutaneous injection was given (aPTT target: 2.0). Patients on chronic therapy with direct anti FII, anti FX oral anticoagulants or warfarin have been switched to enoxaparin sodium 100 IU/kg × 2/die subcutaneously.
In patients with a high-risk of bleeding or abnormal clotting time, a multidisciplinary discussion is organized with haematologists in order to individualize anti-thrombotic prophylaxis on patient’s characteristics.
COVID-19 patients have an increased risk of pulmonary embolism (PE) and deep venous thrombosis (DVT), in particular those who are critically ill [6,7,8, 66,67,68,69]. A recent study enrolling 184 critically ill patients who received at least standard dose thromboprophylaxis found 31% incidence of thrombotic complications . However, the exact frequency of these complications is unknown, and a large data collection through the WHO’s COVID19 Clinical Network is ongoing. Reasons leading to PE and DVT occurrence in COVID-19 patients are unclear. Evidence suggests that elevated D-dimer is common in COVID-19 patients, especially in those at severe stage [7, 9]. It is well known that elevated D-dimer is associated with a higher risk of PE and DVT, as well as other conditions such as cancer, peripheral vascular disease, pregnancy, and inflammatory disease . Inflammation is one of the key mechanisms in the worsening of respiratory conditions in COVID-19 [12, 71]. Autopsy results of multiple series of SARS patients showed that vascular thromboses were common in lung specimens, suggesting an underlying thrombophilia in the lungs . The predominant coagulation abnormalities in patients with COVID-19 suggest a hypercoagulable state called “thromboinflammation” or COVID-19-associated coagulopathy by some experts . It appears to be distinct from disseminated intravascular coagulation (DIC), though DIC has been reported in severely affected patients [7, 72]. Furthermore, reduced physical movements can result in higher risk of DVT in patients’ lower limbs. Finally, a pre-clinical study shows that heparin bind structural proteins of SARS-CoV-2 inducing conformational changes. These data support the repurposing of heparin and its derivatives as potentially anti SARS-CoV-2 agents. For all these reasons, anti-thrombotic prophylaxis should be encouraged in patients with COVID-19 pneumonia determining respiratory failure . We favour pharmacologic prophylaxis of venous thromboembolism consistent with recommendations from expert societies . However, the intensity of thromboprophylaxis, especially in severe and moderate COVID-19 patients, is an outstanding question. Our approach is to apply pharmacological thrombosis prophylaxis in severe and moderate COVID-19 patients towards high prophylactic doses, even in the absence of randomized control trial evidence. However, physicians should start by being vigilant for signs of thrombotic complications, and order appropriate diagnostic tests at a low threshold.
▪ Other therapies are crucial to control signs and symptoms related to ARF and systemic inflammation induced by COVID-19 disease, see Table 4.
Antipyretic medication in critically COVID-19 patients may reduce the risk of haemodynamic instability and hypoxic tissue damage, in particular for elderly patients and/or those with comorbidities . These patients are more vulnerable to elevated physiological demands during high-grade fever presenting an increased risk of dehydration or circulatory dysregulation . For these reasons, as suggested by the Surviving Sepsis Campaign guidelines on management of critically ill patients with COVID-19, anti-piretic agents are used. Furthermore, fluid management, especially in-patients with severe febrile illness, is of paramount importance. Antihypertensive therapy is another controversial area. Systemic hypertension is the most common comorbidity in COVID-19, especially in severe cases . Preliminary studies speculated that the SARS-CoV-2 might enter the human body via angiotensin-converting enzyme 2 (ACE2) on the surfaces of type II alveolar cells [76, 77]. Furthermore, earlier studies about SARS-CoV pathogenesis proved the binding of virus protein S to ACE2 receptor, is associated with ACE2 down-regulation, excessive production of angiotensin by ACE and less vasodilatory function of heptapeptide angiotensin . The renin-angiotensin system (RAS) plays an important role in the occurrence and development of hypertension, and ACE inhibitors (ACEIs) and angiotensin receptor antagonists (ARBs) are the main antihypertensive drugs recommended by the current guidelines. Despite the possible up-regulation of ACE2 by RAS inhibition, there is currently no data proving a causal relationship between ACE2 activity and SARS-CoV-2 associated mortality. Thus, antihypertensive therapy is continued in COVID-19 patients hospitalized in the HDU regardless of pharmacologic.
Clinical stability and clinical failure in COVID-19
The concept of clinical stability is widely adopted into clinical practice for CAP patients [21, 79,80,81]. A variety of criteria for determining clinical improvement have been developed and validated in clinical trials for patients with CAP, including resolution of vital sign abnormalities (heart rate, respiratory rate, blood pressure, oxygen saturation, and temperature), ability to eat, and normal mental status . Failure to achieve clinical stability within 5 days is associated with higher mortality and worse clinical outcomes in CAP patients [79, 82]. Translating the idea of clinical stability from CAP to COVID-19 is difficult because of the characteristics of the virus, the absence of antiviral licensed therapy, and the dis-regulation of the immune system. All these reasons make the evolution of the disease unpredictable with the risk of sudden worsening of pneumonia. Identifing patients who are refractory to initial treatment in COVID-19 pneumonia is of paramount importance. However, no validated definition of clinical failure exists in COVID-19 pneumonia and the same limitations described for clinical stability also applies to clinical failure. Based on our experience, clinical failure could be defined when one of the following criteria is identified: persistence of fever (TC > 37.5 °C) and/or no improvement in inflammatory parameters levels; no improvement or worsening in P/F ratio; tachypnoea and respiratory distress (respiratory rate > 30 breaths/minute); refractory hypoxemia; multiorgan failure; sepsis; new onset of complications.
Criteria to identify patients who are candidate to intubation and invasive support
Two meetings with critical care colleagues are organized every day to discuss patients who are eligible for intubation as well as those who have been transferred from ICU for weaning. All patients with at least one of the following criteria are evaluated for invasive respiratory support: 1) CPAP/NIV dependency for at least 24 h; 2) PaO2/FiO2 ratio < 150; 3) Respiratory rate > 30 and respiratory distress despite optimization of non-invasive respiratory support; 4) Hypercapnia and/or pH < 7.30; 5) Intolerance to respiratory support interface leading to discontinuation of respiratory support; 6) Haemodynamic instability (defined by mean systemic arterial pressure < 65 mmHg and/or diuresis < 0.5 ml/kg/h and/or patient non-responder to fluid challenge and/or amines support).
Clinical recovery and transfer low dependency units (ward)
A patient is considered recovered when all the following criteria are fulfilled: 1) Apiretic patient for at least 72 h; 2) Respiratory rate < 22 breath/minute; 3) SpO2 in room air > 94% (or > 90% in case of chronic pulmonary disease); 4) Two negative samples (at least 24 h between the first sample and the second sample) for SARS-CoV-2.
Patients are considered eligible to be transferred to low-dependency units if all the following criteria are satisfied: 1) Apiretic for at least 24 h without use of anti-piretics drugs; 2) No respiratory support with CPAP, NIV or HFNC; 3) No new onset of complications or cardiovascular deterioration.
The rapid expansion of COVID-19 outbreak is indicative of efficient human-to-human transmission [83, 84]. Virus transmission via respiratory secretions in the form of droplets (> 5 μm) or aerosols (< 5 μm) appears to be the most common form of transmission [84, 85]. Healthcare workers are at high risk of contracting the infection particularly when applying respiratory devices such as oxygen cannulas or NIV, or when performing aerosol generating procedures on patients with COVID-19. Furthermore, the vulnerability in healthcare settings has been proved by the high numbers of reported cases of hospital-acquired infections . Recent studies indicated that aerosol and fomite transmission of SARS-CoV-2 are plausible, as the virus can remain viable in aerosols for multiple hours and on surfaces up to days . Therefore, hospitals present unique challenges during the process of protecting all healthcare providers from an infectious disease outbreak. Personal protective equipment (PPE) is an important component, but not the only one, of a system protecting healthcare providers from COVID-19 cross-infection. Indeed, appropriate use of PPE significantly reduces risk of viral transmission. Recommendations for the process of dressing and undressing for healthcare workers to avoid SARS-CoV-2 infection in COVID-19 unit and the safest use of “respiratory devices” in the COVID-19 unit are described in Table 5. Notably, after the adoption of a dedicated HDU for COVID-19 patients, none of the healthcare providers were infected by SARS-Cov-2. Healthcare providers are weekly screened with nasopharyngeal swab specimen to detect SARS-CoV-2 RNA from the upper respiratory tract. A serological test was performed for each healthcare provider after 3 months of COVID-19 HDU establishment. At the time of writing the present manuscript, only three pulmonologists and one nurse have been tested positive for IgG antibodies. However all of them developed the infection and they were tested positive by nasopharyngeal swab before the establishment of the COVID-19 HDU.
COVID-19 is a complex and heterogeneous disease. Several patients with COVID-19 disease show the signs and symptoms of a dis-regulated inflammatory response to infection leading to a systemic disease. Moreover, hypercoagulability seems an important problem leading to pulmonary embolism and DVT. Lack of experience in managing the disease and lack of highly effective antiviral drug are important limitations. Furthermore, there is need for improvement of ventilatory care. Increasing evidences have been showed the presence of biomarkers, such as IL-6 or ferritin, that can be targeted by off-label treatments. For these reasons a multidisciplinary approach, as the one that is used in our hospital seems to be reasonable. A multidisciplinary involvement of several figures is able to better identify treatable traits of COVID-19 disease, early identify patients who can quickly deteriorate, particularly patients with multiple comorbidities, and better manage complications related to off-label treatments. The management of patients in COVID-19 dedicated units is advisable for segregation purpose as well as for infection control. All the procedures adopted in our hospital cannot be generalized in other hospitals and different healthcare systems. However, we think that our experience and our point of view can be helpful for countries and hospitals that are now starting to face the COVID-19 outbreak.
Availability of data and materials
World Health Organization
Severe Acute Respiratory Syndrome coronavirus 2
High Flow Nasal Cannula
Non Invasive Ventilation
Invasive Mechanical Ventilation
Acute Respiratory Failure
Intensive Care Unit
High Dependency Unit
Standard Operating Procedures
Multi Drug Resistant
Continuous Positive Airway Pressure
Do Not Resuscitate
Do Not Intubate
Randomized Control Trial
Community Acquired Pneumonia
Positive End Expiratory Pressure
Zero End Expiratory Pressure
Blood Gas Analysis
Centers Disease Control
Infectious Diseases Society of America
Acute Respiratory Distress Syndrome
Methicillin Resistant Staphilococcus Aureus
Deep Venous Thrombosis
Disseminated Intravascular Coagulation
Angiotensin Converting Enzyme 2
Angiotensin Receptor Antagonists
Personal Protective Equipment
World Health Organization. Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV). https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov). Published January 30, 2020. Accessed 28 Mar 2020.
World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19%2D%2D-11-march-2020. Published March 11, 2020. Accessed 20 Mar 2020.
World Health Organization. WHO director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020. Published February 11, 2020. Accessed 28 Mar 2020.
Fisher D, Wilder-Smith A. The global community needs to swiftly ramp up the response to contain COVID-19. Lancet. 2020;S0140–6736(20):30679–6.
Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China [published online ahead of print, 2020 Mar 13]. Jama Intern Med. 2020;180(7):934–43.
Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential effects of coronaviruses on the cardiovascular system: a review [published online ahead of print, 2020 Mar 27]. JAMA Cardiol. 2020. https://doi.org/10.1001/jamacardio.2020.1286.
Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19 [published online ahead of print, 2020 Apr 17]. J Thromb Haemost. 2020. https://doi.org/10.1111/jth.14849.
Poissy J, Goutay J, Caplan M, et al. Pulmonary embolism in COVID-19 Patients: Awareness of an increased prevalence [published online ahead of print, 2020 Apr 24]. Circulation. 2020. https://doi.org/10.1161/CIRCULATIONAHA.120.047430.
Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of Coronavirus Disease 2019 in China [published online ahead of print, 2020 Feb 28]. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2002032.
Grasselli G, Pesenti A, Cecconi M. Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response [published online ahead of print, 2020 Mar 13]. JAMA, 2020. https://doi.org/10.1001/jama.2020.4031.
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China Lancet. 2020;395(10223):497 Epub 2020 Jan 24.
Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033 Epub 2020 Mar 16.
Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19 [published online ahead of print, 2020 Mar 18]. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2001282.
Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 - preliminary report [published online ahead of print, 2020 May 22]. N Engl J Med. 2020;NEJMoa2007764. https://doi.org/10.1056/NEJMoa2007764.
Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9(396):eaal3653.
Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–71.
Matthay MA, Aldrich JM, Gotts JE. Treatment for severe acute respiratory distress syndrome from COVID-19 [published online ahead of print, 2020 Mar 20]. Lancet Respir Med. 2020. https://doi.org/10.1016/S2213-2600(20)30127-2.
Gattinoni L, et al. COVID-19 pneumonia: different respiratory treatment for different phenotypes? Intensive Care Med. 2020;46(6):1099–102.
Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome [published correction appears in Lancet Respir Med. 2020 Feb 25;:]. Lancet Respir Med 2020;8(4):420–422.
Chu DK, Kim LH, Young PJ, et al. Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis. Lancet. 2018;391:1693–705.
Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia: an official clinical practice guideline of the American Thoracic Society and Infectious Disease Society of America. Am J Respir Crit Care Med. 2019;200:e45–67.
Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections--full version. Clin Microbiol Infect. 2011;17(Suppl. 6):E1–59.
Cosentini R, Brambilla AM, Aliberti S, et al. Helmet continuous positive airway pressure vs oxygen therapy to improve oxygenation in community-acquired pneumonia: a randomized, controlled trial. Chest. 2010;138(1):114–20.
Rochwerg B, Brochard L, Elliott MW, et al. Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. Eur Respir J. 2017;50(2):1602426–46.
Brochard L, Slutsky A, Pesenti A. Mechanical ventilation to minimize progression of lung injury in acute respiratory failure. Am J Respir Crit Care Med. 2017;195:438–42.
Pan C, Chen L, Lu C, et al. Lung Recruitability in SARS-CoV-2 Associated Acute Respiratory Distress Syndrome: A Single-center, Observational Study [published online ahead of print, 2020 Mar 23]. Am J Respir Crit Care Med. 2020. https://doi.org/10.1164/rccm.202003-0527LE.
Paolini V, Faverio P, Aliberti S, et al. Positive end expiratory pressure in acute hypoxemic respiratory failure due to community acquired pneumonia: do we need a personalized approach? PeerJ. 2018;6:e4211.
Ding L, Wang L, Ma W, He H. Efficacy and safety of early prone positioning combined with HFNC or NIV in moderate to severe ARDS: a multi-center prospective cohort study. Crit Care. 2020;24(1):28 Published 2020 Jan 30.
Pérez-Nieto OR, Guerrero-Gutiérrez MA, Deloya-Tomas E, Ñamendys-Silva SA. Prone positioning combined with high-flow nasal cannula in severe noninfectious ARDS. Crit Care. 2020;24(1):114 Published 2020 Mar 23.
Caputo ND, Strayer RJ, Levitan R. Early self-proning in awake, non-intubated patients in the emergency department: a single ED's experience during the COVID-19 pandemic. Acad Emerg Med. 2020;27(5):375–8. https://doi.org/10.1111/acem.13994.
Gattinoni L, Protti A. Ventilation in the prone position: for some but not for all? CMAJ. 2008;178:1174–6.
Gattinoni L, Coppola S, Cressoni M, Busana M, Rossi S, Chiumello D. Covid-19 does not lead to a “typical” acute respiratory distress syndrome [published online ahead of print, 2020 Mar 30]. Am J Respir Crit Care Med. 2020. https://doi.org/10.1164/rccm.202003-0817LE.
Simonds AK, Hanak A, Chatwin M, et al. Evaluation of droplet dispersion during non-invasive ventilation, oxygen therapy, nebuliser treatment and chest physiotherapy in clinical practice: implications for management of pandemic influenza and other airborne infections. Health Technol Assess (Winchester, England). 2010;14(131):–72.
Ferioli M, Cisternino C, Leo V, et al. Protecting healthcare workers from SARS-CoV-2 infection: practical indications. Eur Respir Rev. 2020;29:200068.
Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial [published online ahead of print, 2020 Mar 20]. Int J Antimicrob Agents. 2020;56(1):105949.
Arshad S, Kilgore P, Chaudhry ZS, et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int J Infect Dis. 2020;97:396–403. https://doi.org/10.1016/j.ijid.2020.06.099.
Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [published online ahead of print, 2020 Mar 9]. Clin Infect Dis. 2020;71(15):732–9.
Liu J, Cao R, Xu M, Wang X, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16.
McGhie TK, Harvey P, Su J, Anderson N, et al. Electrocardiogram abnormalities related to anti-malarials in systemic lupus erythematosus. Clin Exp Rheumatol. 2018;36(4):545–51.
Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19 [published online ahead of print, 2020 Jul 23]. N Engl J Med. 2020:NEJMoa2019014. https://doi.org/10.1056/NEJMoa2019014. Online ahead of print.
Mahévas M, Tran VT, Roumier M, et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data [published correction appears in BMJ. 2020 Jun 18;369:m2328]. BMJ. 2020;369:m1844 Published 2020 May 14. https://doi.org/10.1136/bmj.m1844.
RECOVERY trial investigators. No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19. https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19. Accessed 29 July 2020.
Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial [published correction appears in Lancet. 2020 May 30;395(10238):1694]. Lancet. 2020;395(10236):1569–78. https://doi.org/10.1016/S0140-6736(20)31022-9.
Shakoory B, Carcillo JA, Chatham WW, et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase iii trial. Crit Care Med. 2016;44:275–81.
Ramírez J, Cañete JD. Anakinra for the treatment of rheumatoid arthritis: a safety evaluation. Expert Opin Drug Saf. 2018;17(7):727–32.
Jones G, Ding C. Tocilizumab: a review of its safety and efficacy in rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord. 2010;3:81–9.
Geng Z, Yu Y, Hu S, Dong L, et al. Tocilizumab and the risk of respiratory adverse events in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomised controlled trials. Clin Exp Rheumatol. 2019;37:318–23.
Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020; published online March 3.
ClinicalTrials.gov Identifier: https://clinicaltrials.gov/ct2/show/NCT04315480.
Sciascia S, Aprà F, Baffa A, et al. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. Clin Exp Rheumatol. 2020;38(3):529–32.
Guaraldi G, Meschiari M, Cozzi-Lepri A, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020;2(8):e474–84.
Morena V, Milazzo L, Oreni L, et al. Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan. Italy Eur J Intern Med. 2020;76:36–42.
Cavalli G, De Luca G, Campochiaro C, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020;2(6):e325–31.
World Health Organization. Novel Coronavirus (2019-nCoV) technical guidance: Patient management. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/patient-management. Accessed 02 Feb 2020.
Centers for Disease Control and Prevention. Interim Clinical Guidance for Management of Patients with Confirmed 2019 Novel coronavirus (2019-nCoV) infection, Updated February 12, 2020. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html. Accessed 14 Feb 2020.
Bhimraj A, Morgan RL, Shumaker A, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. IDSA. Clin Infect Dis. 2020;ciaa478. https://doi.org/10.1093/cid/ciaa478. Online ahead of print.
Alhazzani W, Moller MH, Arabi YM, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med. 2020;46(5):854–87.
UK Government press release. World first coronavirus treatment approved for NHS use by government https://www.gov.uk/government/news/world-first-coronavirus-treatment-approved-for-nhs-use-by-government. Accessed 19 June 2020.
Lee N, Choi KW, Chan PK, et al. Outcomes of adults hospitalised with severe influenza. Thorax. 2010;65:510–5.
McGeer A, Green KA, Plevneshi A, et al. Toronto invasive bacterial diseases network. Antivira therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis. 2007;45:1568–75.
Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med. 2003;348(19):1866–74.
Mosholder AD, Mathew J, Alexander JJ, Smith H, Nambiar S. Cardiovascular risks with azithromycin and other antibacterial drugs. N Engl J Med. 2013;368(18):1665–8.
Svanström H, Pasternak B, Hviid A. Use of azithromycin and death from cardiovascular causes. N Engl J Med. 2013;368(18):1704.
Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012;366(20):1881.
Lu ZK, Yuan J, Li M, et al. Cardiac risks associated with antibiotics: azithromycin and levofloxacin. Expert Opin Drug Saf. 2015;14(2):295–303.
Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089–98. https://doi.org/10.1007/s00134-020-06062-x.
Danzi GB, Loffi M, Galeazzi G, Gherbesi E. Acute pulmonary embolism and COVID-19 pneumonia: a random association? Eur Heart J. 2020;41(19):1858.
Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19 [published online ahead of print, 2020 Apr 10]. Thromb Res. 2020;S0049–3848(20)30120–1. https://doi.org/10.1016/j.thromres.2020.04.013.
Artifoni M, Danic G, Gautier G, et al. Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors. J Thromb Thrombolysis. 2020;50(1):211–6. https://doi.org/10.1007/s11239-020-02146-z.
Toplis E, Mortimore G. The diagnosis and management of pulmonary embolism. Aust Fam Physician. 2010;39:462–6.
Conti P, Ronconi G, Caraffa A, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies [published online ahead of print, 2020 Mar 14]. J Biol Regul Homeost Agents. 2020;34(2):1.
Cugno M, Meroni PL, Gualtierotti R, et al. Complement activation in patients with COVID-19: A novel therapeutic target [published online ahead of print, 2020 May 14]. J Allergy Clin Immunol. 2020;146(1):215–7. https://doi.org/10.1016/j.jaci.2020.05.006.
Kiekkas P, Aretha D, Bakalis N, Karpouhtsi I, Marneras C, Baltopoulos GI. Fever effects and treatment in critical care: literature review. Aust Crit Care. 2013;26(3):130–5. https://doi.org/10.1016/j.aucc.2012.10.004.
Launey Y, Nesseler N, Mallédant Y, Seguin P. Clinical review: fever in septic ICU patients--friend or foe? Crit Care. 2011;15(3):222. https://doi.org/10.1186/cc10097.
Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis [published online ahead of print, 2020 Mar 26]. Eur Respir J. 2020:2000547. https://doi.org/10.1183/13993003.00547-2020.
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565–74.
Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–3.
Kouhpayeh S. The molecular story of COVID-19; NAD+ depletion addresses all questions in this infection; Preprints 2020.
Garin N, Felix G, Chuard C, et al. Predictors and implications of early clinical stability in patients hospitalized for moderately severe community-acquired pneumonia. PLoS One. 2016;11:e0157350.
Halm EA, Fine MJ, Marrie TJ, Coley CM, Kapoor WN, Obrosky DS, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA. 1998;279:1452–7.
Aliberti S, Zanaboni AM, Wiemken T, et al. Criteria for clinical stability in hospitalised patients with community-acquired pneumonia. Eur Respir J. 2013;42:742–9.
Menéndez R, Torres A, Zalacaín R, Aspa J, Martín Villasclaras JJ, Borderías L, et al. Neumofail Group. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax. 2004;59:960–5.
Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel 180 coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395:514–181 23.
Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382(13):1199–207.
Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020;382(12):1177–9.
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention [published online ahead of print, 2020 Feb 24]. JAMA. 2020. https://doi.org/10.1001/jama.2020.2648.
van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med. 2020;382(16):1564–7.
Disposition of the Italian Minister of Health n. 5443. New indications and clarifications. http://www.trovanorme. salute.gov.it/norme/ Date last updated: 22 February 2020; date last accessed: 30 Mar 2020.
Respiratory Care Committee of Chinese Thoracic Society. Expert consensus on preventing nosocomial transmission during respiratory care for critically ill patients infected by 2019 novel coronavirus pneumonia. ZhonghuaJie He He Hu Xi Za Zhi. 2020;17:E020.
World Health Organization. Rational use of personal protective equipment for coronavirus disease 2019 (COVID-19) Interim guidance. https://apps.who.int/iris/bitstream/handle/10665/331215/WHO-2019-nCovIPCPPE_use-2020.1-eng.pdf Date last updated: 27 February 2020; date last accessed: 30 Mar 2020.
Tran K, Cimon K, Severn M, et al. Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: a systematic review. PLoS One. 2012;7:e35797.
Critical Care Committee of Chinese Association of Chest Physician, Respiratory and Critical Care Group of Chinese Thoracic Society, Respiratory care group of Chinese Thoracic Society. Conventional respiratory support therapy for Severe Acute Respiratory Infections (SARI): Clinical indications and nosocomial infection prevention and control. ZhonghuaJie He He Hu Xi Za Zhi. 2020;43:E015.
COVID-19 HDU: Cavallini Mirta, Contarini Martina, Dellafiore Silvia, Morlacchi Letizia Corinna, Ori Margherita, Rossetti Valeria, Bassi Linda, Bindo Francesco, Misuraca Sofia, Pilocane Tommaso, Pirracchio Fabio, Vigni Annalisa, Bertoletti Alessandra, Cao Michela, Child Maurice, Colombo Federico, Dhiel Livia Maria Carlotta, Fedele Antonella, Gigli Lorenzo, Manfredini Ruggiero, Meazza Roberto, Montanari Paola, Mircoli luca, Pomidossi Guido Sozzi Annapaola, Rossetti Enrico, Spaziani Domenico, Strata Maria, Tonella Tatiana, Rota Irene, Vicenzi Marco, Belmonte Marta, Cusmano Ignazio, De Nora Marialessia, De Zan Valentina, Di Cosola Roberta, D’Errico Andrea, Ferrari Gabriele, Mallia Vincenzo, Ratti Angelo, Sabato Feerica, Schillaci Matteo, Carai Claudia, Ceruti Clara, Colombo Alessia, Cuccarini Filippo, Retucci Mariangela, Sapienza Enzo, Tammaro Serena, Ventrice Maria, Travascio Rosina, Leoni Federica, Sangiovanni Marta, Maiorano Antonella, Soloperto Silvia, Russo Antonio, Chittaro Anna, Cannia Alice, Brambilla Elena, Tonolini Pietro, La Iacona Luca, Parasiliti Collazzo Anna, Bianchini Elena, Brunetti Danilo, Dell’ Orefice Nicolina, Galati Roberta, Zuccotti Ivano, Esposito Giuseppe, Nasuto Cosimo, Colombi Greta, Albini Irene, Sartirana Cristina, Mariano Irene, Pandolfino Gabriele, Paternico’ Salvatrice, Cavagnuolo Domenico, Nizzola Sara, Cresci Mimma, Barbini Roberto, Mallardo Andrea, Saragozza Giuseppina, Pesce Elisa, Rizzi Donato, Della Cerra Lucia, Vella Saverio, Fessehauie Bisrat, Longo Marco, Dotti Anna, Presazzi Elena, Sarpa Anna Lucia, Vinci Elisabetty, Giannantonio Laura, Moretti Ilaria, Rigamonti Alice, Esposito Martha, Ariete Giovanni, Iacovelli Giuseppina, Licitra Ivana, Bencivenga Antonietta, Rossi Giuseppe, Bertinelli Luigi, Morrusco Mirella, Martone Annunziata, Spedicato M. Chiara, Tsysar Iryna, Castelli Ivan, Morra Giuseppe, Mingiano Rita, Ganci Girolama, Ammaturo Anna, Pascazio Nicola, Ghirimoldi Silvana, Ippolito Gaetana, Maffia Rocco, Hurdubaia Elena, Toscano Marco, Condori Crespo Cherly, Provenzano Adriana.
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Ethics approval and consent to participate
Consent for publication
Prof. Aliberti reports grants and personal fees from Bayer Healthcare, grants and personal fees from Aradigm Corporation, grants and personal fees from Grifols, personal fees from Astra Zeneca, personal fees from Basilea, personal fees from Zambon, personal fees from Novartis, personal fees from Raptor, grants and personal fees from Chiesi, personal fees from Actavis UK Ltd., personal fees from Horizon, grants and personal fees from INSMED, outside the submitted work. Dr. Mantero reports other from Astra-Zeneca, personal fees and other from MadicAir, other from Vivisol, outside the submitted work. Prof. Blasi reports grants and personal fees from astrazeneca, grants from bayer, grants and personal fees from chiesi, grants and personal fees from gsk, personal fees from guidotti, personal fees from grifols, grants and personal fees from insmed, personal fees from menarini, personal fees from mundipharma, personal fees from novartis, grants and personal fees from pfizer, personal fees from zambon, outside the submitted work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Aliberti, S., Amati, F., Pappalettera, M. et al. COVID-19 multidisciplinary high dependency unit: the Milan model. Respir Res 21, 260 (2020). https://doi.org/10.1186/s12931-020-01516-8
- High dependency unit
- Multidisciplinary approach